Aclaris Therapeutics

Stifel reiterated a Hold on Aclaris Therapeutics and raised its price target to $4, citing optimism about the company’s multi-targeting immunology approaches. Aclaris reported positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 and is awaiting top-line Phase 1b proof-of-concept data, while advancing ATI-2138 for lichen planus. Q1 revenue rose to $2.0 million from $1.5 million driven by higher royalties, but the company posted a net loss of $19.8 million versus $15.1 million a year earlier. » Más en finance.yahoo.com

Aclaris disclosed full phase‑1a results for ATI‑052: the bispecific antibody showed an estimated half‑life of about 45 days, dose‑proportional pharmacokinetics, sustained inhibition of relevant biomarkers and good tolerability with no safety signals. Recruitment for phase‑1b studies in asthma and atopic dermatitis is ongoing, with results expected in H2 2026 and a phase‑2b program for asthma planned for Q4 2026. In addition, Aclaris plans a phase‑2b basket study with the dual inhibitor ATI‑2138 in erosive mucosal and cutaneous lichen planus in H2 2026; there are currently no FDA‑approved therapies for lichen planus. » Más en de.investing.com

Aclaris will release the full results of the phase 1a study of ATI-052 and the outcome of the selection process for the lead indication of the ITK/JAK3 inhibitor ATI-2138 on Tuesday before the market opens. The company will host a webcast and conference call with a presentation at 8:30 a.m. EST. Specific study data or the chosen indication were not disclosed in advance; analyst price targets range from $3 to $16. Aclaris emphasizes its clinical pipeline for immune-inflammatory diseases and reports a strong liquidity position relative to its debt. » Más en de.investing.com